As of 2025-11-08, the Intrinsic Value of Agios Pharmaceuticals Inc (AGIO) is 118.55 USD. This Agios valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 40.67 USD, the upside of Agios Pharmaceuticals Inc is 191.50%.
The range of the Intrinsic Value is 99.64 - 147.64 USD
Based on its market price of 40.67 USD and our intrinsic valuation, Agios Pharmaceuticals Inc (AGIO) is undervalued by 191.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 99.64 - 147.64 | 118.55 | 191.5% |
| DCF (Growth 10y) | 110.64 - 160.27 | 130.29 | 220.4% |
| DCF (EBITDA 5y) | 166.07 - 184.73 | 175.11 | 330.6% |
| DCF (EBITDA 10y) | 159.95 - 190.94 | 174.57 | 329.2% |
| Fair Value | -172.66 - -172.66 | -172.66 | -524.54% |
| P/E | (96.55) - 192.68 | 26.17 | -35.7% |
| EV/EBITDA | (118.61) - 189.71 | 34.59 | -15.0% |
| EPV | (51.54) - (68.72) | (60.13) | -247.9% |
| DDM - Stable | (31.78) - (64.99) | (48.39) | -219.0% |
| DDM - Multi | 45.23 - 76.03 | 57.04 | 40.3% |
| Market Cap (mil) | 2,362.93 |
| Beta | 1.77 |
| Outstanding shares (mil) | 58.10 |
| Enterprise Value (mil) | 2,270.22 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.89% |
| Cost of Debt | 5.00% |
| WACC | 8.28% |